Emerald Advisers LLC Purchases 770,586 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Emerald Advisers LLC increased its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 112.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,456,033 shares of the medical technology company's stock after purchasing an additional 770,586 shares during the period. Emerald Advisers LLC owned approximately 1.03% of Alphatec worth $13,366,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. R Squared Ltd bought a new stake in shares of Alphatec during the 4th quarter worth about $29,000. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after purchasing an additional 4,234 shares during the last quarter. Newton One Investments LLC acquired a new stake in Alphatec in the 4th quarter worth approximately $50,000. XTX Topco Ltd bought a new stake in Alphatec during the third quarter worth approximately $69,000. Finally, AlphaQuest LLC acquired a new position in Alphatec during the fourth quarter valued at approximately $80,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Patrick Miles sold 6,687 shares of the firm's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the transaction, the chief executive officer now owns 5,501,715 shares in the company, valued at $66,020,580. This trade represents a 0.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the business's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the completion of the sale, the executive vice president now directly owns 502,311 shares in the company, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 337,321 shares of company stock worth $3,828,060. Corporate insiders own 22.80% of the company's stock.

Remove Ads

Alphatec Stock Performance

Shares of ATEC stock traded down $0.20 during mid-day trading on Thursday, reaching $10.05. The stock had a trading volume of 804,842 shares, compared to its average volume of 1,950,863. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $14.54. The firm has a market cap of $1.45 billion, a PE ratio of -7.85 and a beta of 1.39. The firm's 50 day simple moving average is $10.89 and its 200 day simple moving average is $8.93. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The firm had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research note on Thursday, February 27th. Barclays increased their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Finally, Piper Sandler lifted their price target on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Alphatec currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.